Larisa Petrison, PAC
Physician Assistant · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Larisa Petrison’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 23% of their 47 Part D prescriptions in 2016. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2016 | 47 | 14 | 23% (11) | None | $2,202 |
| 2015 | 96 | 36 | None | None | $9,347 |
| 2014 | 48 | 21 | None | None | $29,720 |
| 2013 | 20 | None | None | 65% | $49,342 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2014: 1 drug
| Enoxaparin | 11 | $4,192 | $381 |
Money from drug and device companies
$535 in 2025
| 2025 | 5 | 5 | None | $535 |
| 2024 | 4 | 4 | None | $482 |
| 2023 | 3 | 3 | None | $347 |
| 2022 | 4 | 5 | None | $506 |
| 2021 | 1 | 1 | None | $102 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Gilead Sciences | None | $127 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $112 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $108 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | None | $98 | 1 payment
|
| Chiesi USA | Cleviprex | $89 | 1 payment
|
See all 5 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-10 | None | $112 |
| Gilead Sciences | Meals · 2025-09-17 | None | $127 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-19 | Fasenra | $108 |
| Chiesi USA | Meals · 2025-05-15 | Cleviprex | $89 |
| Otsuka Pharmaceutical Development & Commercialization | Meals · 2025-04-24 | None | $98 |
See earlier years (2024, 2023, 2022, 2021)
2024: $482
| Genzyme | Fabrazyme | $144 | 1 payment
|
| Gilead Sciences | Epclusa | $122 | 1 payment
|
| Si-Bone | None | $112 | 1 payment
|
| Vertex Pharmaceuticals | None | $104 | 1 payment
|
2023: $347
| Abbvie | Vraylar | $125 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | None | $116 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $106 | 1 payment
|
2022: $506
| Amgen | Evenity | $214 | 2 payments
|
| Gilead Sciences | Epclusa | $125 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $107 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $60 | 1 payment
|
2021: $102
| Amgen | Repatha | $102 | 1 payment
|
Professional record
- NPI
- 1902965676
- Licence
- CA PA17434
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1804 Embarcadero Rd, Mc:5548, Palo Alto, CA, 94303
- NPI first listed
- 2006-12-08
- NPI last updated
- 2014-09-25
This is when the NPI record was last certified, not a medical board exam.